Findings {#Sec1}
========

Background {#Sec2}
----------

Ticks are among the most important vectors of a wide range of pathogens causing human and animal diseases, and several classes of acaricide are widely used to control tick infestation \[[@CR1], [@CR2]\]. However, there is an increasing number of reports of resistance to acaricides including macrocyclic lactones \[[@CR3]\]. One of the most widely studied mechanisms of drug resistance is associated with the protein family of ABC transporters, which transport toxic substances outside the cell, thereby reducing their concentration inside the cell \[[@CR4]\]. These efflux pumps are able to eliminate both endogenous and exogenous toxins and are an important "first-line" defence mechanism. Recent studies have shown that ABC transporters are present in a wide range of organisms, including mammals and arthropods, and have been implicated in drug resistance in ticks \[[@CR5]--[@CR7]\]. A recent study reported that over-expression of a gene encoding for ABC-multidrug transporters was associated with in vitro-induced resistance to ivermectin in the tick cell line BME26 \[[@CR8]\], derived from embryos of the cattle tick *Rhipicephalus* (*Boophilus*) *microplus* \[[@CR9]\]. In addition, ABC transporters may be involved in detoxification in the brown dog tick *Rhipicephalus sanguineus* (*sensu lato*) \[[@CR10]\]. Despite increasing evidence that ABC transporters are likely to be involved in acaricide resistance in ticks, there have been no studies in *Ixodes ricinus*, one of the most important vectors of pathogens causing tick-borne diseases in Europe. Ixodid tick cell lines have already been used as a model for the study of drug resistance \[[@CR8], [@CR11]\]. The development of an in vitro model for the study of molecular resistance mechanisms and the screening of potential genetic markers of resistance in *I. ricinus* would be of great scientific interest.

The aim of the present study was to evaluate the expression of selected members of the ABC transporters subfamily B (ABCB1, ABCB6, ABCB8 and ABCB10) in vitro, following ivermectin treatment of the *I. ricinus* cell line IRE/CTVM19. Ivermectin was chosen as the test acaricide both because of its use in previous published studies on ABC transporters \[[@CR6]--[@CR8], [@CR10]\] and because it has been shown to be active against *I. ricinus* ticks \[[@CR12]\].

Methods {#Sec3}
=======

Reagents {#Sec4}
--------

All reagents were purchased from Sigma Aldrich (Milan, Italy) except where indicated.

Cell line maintenance {#Sec5}
---------------------

Cells of the *I. ricinus* embryo-derived cell line IRE/CTVM19 \[[@CR13]\] were seeded in flat sided 10 ml tubes (Nunc) in Leibovitz's L-15 medium (Life Technologies, Milan, Italy) supplemented with 20 % fetal bovine serum, 10 % tryptose phosphate broth, 2mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 μg/ml) and incubated at 28 °C. Medium (3/4 volume) was replaced weekly and cells were split at intervals of at least 15 days.

Treatment of IRE/CTVM19 cells with ivermectin {#Sec6}
---------------------------------------------

IRE/CTVM19 cells seeded at a concentration of 3 × 10^6^ cells/ml in 2 ml culture medium per tube were treated immediately with different concentrations of ivermectin in 0.1 % DMSO (11 μM, 22 μM or 33 μM). Untreated cells and cells treated with 0.1 % DMSO only served as controls. Cultures were incubated for 10 days and medium was changed on the seventh day. Replacement media contained the same concentrations of ivermectin as reported above.

Growth curve and cell viability {#Sec7}
-------------------------------

For growth rate analysis, four replicate tubes were used per treatment. On days 0, 5 and 10, a small aliquot of cell suspension was harvested from each tube, labelled with Trypan Blue 0.4 % w/v and counted using a haemocytometer. A test of cell viability was also performed on day 5 of treatment using the LIVE/DEAD Fixable Near-IR stain kit (Life Technologies). Cells were stained according to the manufacturer's instructions and analysed by flow cytometry. Flow cytometry was performed using a BD FACSVerse (BD Biosciences, Stockholm, Sweden) equipped with 488 nm blue and 633 nm red lasers, and results were analysed using the FACSDiva (BD Biosciences) software. Cells frozen at -80 °C and thawed three times were used as negative controls.

RNA extraction and determination of gene expression profile after acaricide treatment {#Sec8}
-------------------------------------------------------------------------------------

On day 10 following the start of ivermectin treatment, RNA was extracted from samples of resuspended cells from each replicate culture using an RNeasy Mini Kit (Qiagen) following the manufacturer's instructions. RNA was measured by spectrophotometric analysis for quality and content and then converted into cDNA using a QuantiTect Reverse Transcription Kit (Qiagen). The resultant cDNAs were used as templates for molecular analysis. To date, there is no published information about *I. ricinus* sequences for any of the pumps under investigation (those encoded by the ABCB1, ABCB6, ABCB8 and ABCB10 genes); thus primers were designed (Table [1](#Tab1){ref-type="table"}) based on conserved regions of sequences of selected ABC transporters of *I. scapularis* available in VectorBase (ABCB1: ISCW004310; ABCB6: ISCW021257; ABCB8: ISCW005908; ABCB10: ISCW008199) \[[@CR14]\]. As an endogenous control, the *I. ricinus* β-actin gene was chosen and primers were designed based on the partial sequence available in Genbank (HQ682101). Primers were first tested in a traditional PCR using cDNA derived from an untreated control IRE/CTVM19 culture and reactions were run on a 2 % agarose gel stained with SYBR Safe Gel and examined under UV light (UView mini Transilluminator, Biorad) (Fig. [1](#Fig1){ref-type="fig"}). The amplification fragments, obtained using standard PCR conditions and the thermal profile indicated below, were sequenced in order to confirm the specificity of the amplification. The resultant sequences were deposited in the EMBL Nucleotide Sequence Database (ABCB6: LT222036; ABCB8: LT222037; ABCB10: LT222038).Table 1Primers used in the present study for evaluation of expression of the ABC subfamily B genes (ABCB1, ABCB6, ABCB8 and ABCB10) in the *Ixodes ricinus* cell line IRE/CTVM19Primer sequencesABCB1F:5′ --TCTTTGCCGTCTTCTACAG-- 3′R:5′ --CAGGTTCTCTCCAGCGAT-- 3′ABCB6F:5′ --AGACTATGTCCTCTTCCTCA-- 3′R:5′ --CATCTATCACCTCTGCCTT-- 3′ABCB8F:5′ --ATCAGGAACGCCGACATC-- 3′R:5′ --AGTTTCCAGTAGACACCCTT-- 3′ABCB10F:5′ --TGTCCTAACCATTGCTCACA-- 3′R:5′ --TGATGTTCCACTAATGTCCG-- 3′β-ActinF:5′ --CACGGCATCGTGACCAACTG-- 3′R:5′ --CGAACATGATCTGAGTCATCTTCTC-- 3′Fig. 1Primer couples tested in traditional PCR. All fragments were approximately 101--157 bp long. The no-template control (NTC) presented a spot due to primer dimerization

ABC-B subfamily protein expression was then evaluated by quantitative RT-PCR, using the SYBR Green master mix kit (EuroClone), according to the manufacturer's instructions. The final concentration of each primer in all the reactions was 0.4 μM. The amplification protocol was characterised by a denaturation step (95 °C for 2 min) and 45 repeated cycles (95 °C for 10 s; 56 °C for 15 s; 72 °C for 20 s). Fluorescence signals were collected in every cycle and the presence of nonspecific products was excluded through analysis of the melting curves. Results were presented as the mean ± S.E.M. of three experiments with four replicates each, managed by CFX Manager software (Biorad) and expressed as Relative Normalised Expression (ΔΔCq).

Data analysis {#Sec9}
-------------

One-way ANOVA with Dunnett's *post-hoc* test was performed using GraphPad Prism version 6(GraphPad Software, San Diego California USA, [www.graphpad.com](http://www.graphpad.com/)). *P*-values \< 0.05 were considered statistically significant.

Results and discussion {#Sec10}
======================

Growth curve analysis revealed a doubling-time of approximately ten days for IRE/CTVM19 cells under all conditions. IVM treatment modified cell morphology and adherance to the plastic tube, but did not alter cell viability (Fig. [2](#Fig2){ref-type="fig"}). As measured by Trypan Blue exclusion assay (data not shown) and flow-cytometry (Fig. [3](#Fig3){ref-type="fig"}), viability was 92 % in the untreated control cells and between 84 % and 88 % in cells treated with DMSO alone or with IVM. Differences between groups were not significant.Fig. 2Morphology and density of IRE/CTVM19 cell line following IVM treatment. Increasing concentration of IVM (**b**: 11 μM; **c**: 22 μM; **d**: 33 μM) determined larger and more vacuolated cells compared to untreated control (**a**). Pictures were captured at 100 × magnificationFig. 3IRE/CTVM19 cell viability on day 5 of cultivation either untreated (L-15), treated with 0.1% DMSO alone (DMSO 0.1 %) or treated with ivermectin (IVM) in 0.1 % DMSO at concentrations of 11, 22 or 33 μM. Cells were evaluated by flow cytometry following Live vs. Dead® staining and data represents the mean of four replicate tubes ± S.E.M. Viability measured by Trypan Blue exclusion on days 5 and 10 was comparable (data not shown)

Quantitative RT-PCR analysis showed that ABC gene expression was present in IRE/CTVM19 cells but not significantly modulated following ivermectin treatment (Fig. [4](#Fig4){ref-type="fig"}). Expression of the ABCB1 gene was not detectable at any time point in any condition (data not shown). ABCB6, ABCB8 and ABCB10 were detected, but no significant differences were seen between untreated and treated cultures or between different doses of IVM.Fig. 4Expression of ABCB6, ABCB8 and ABCB10 genes in IRE/CTVM19 cells untreated (L-15), treated with 0.1% DMSO alone (DMSO) or treated with different concentrations of ivermectin (IVM) in 0.1% DMSO. Results were expressed as Relative Normalised Expression (ΔΔCt) vs expression of the housekeeping gene (β-Actin) and were presented as the mean ± S.E.M. of three experiments performed with four replicates each

To the authors' knowledge, this is the first report of expression and modulation of ABC transporters in an *I. ricinus*-derived cell line. The relative expression of ABC genes in ivermectin-treated cells ranged between 0.5 and 1.6 fold compared to the time zero control. Interestingly, ABCB8 expression showed a particular, biphasic dose-response relationship, with a low-dose stimulation and a high-dose return to the control level, as reported by Calabrese for drug-resistant vertebrate cell lines \[[@CR15]\]. The results presented here indicate the need for further study.

Furthermore, ivermectin has been incriminated as an inhibitor of detoxification mechanisms in mammalian cell lines \[[@CR16]\] and the results regarding ABCB8 in the present study suggest that the inhibitor effect may also be true for *I. ricinus* tick cell lines. In the only other similar in vitro study published so far \[[@CR8]\], a clear role for ivermectin could be demonstrated both in terms of establishment of a lethal concentration 50 (LC~50~) and of a resistant tick cell sub-line. In that study, up-regulation of several ABC genes (ABCB10, ABCC1, ABCB7, ABCC2) was observed in the ivermectin-resistant cell sub-line BME26-IVM.

Interestingly, the *I. ricinus* cell line used in the present study was able to tolerate a much higher concentration of ivermectin, 30 μg/ml (33 μM), than the unselected BME26 cell line that did not survive after exposure to a concentration of ivermectin of 12.5 μg/ml or the resistant sub-line BME26-IVM for which the LC~50~ was calculated as 15.1 μg/ml \[[@CR7]\]. Differences between the biology of the two tick species from which the cell lines were derived (*I. ricinus* and *R. microplus*), between the phenotypic composition of the cell lines themselves and/or in the culture conditions used (such as medium composition and incubation temperature) may explain the differences in the outcome of treatment and should be taken into account when refining the in vitro model of *I. ricinus*. Finally, it would be of interest to develop this in vitro model with cell lines from other economically important tick species and to evaluate the effect of different acaricides that have been reported to be losing their efficacy in the field \[[@CR17]\].
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